Evidence mapPaperPMID 39688651Full record

ReviewImmunogenetics2024

Syndecan-1: a key player in health and disease.

Lara Diab, Sahar Al Kattar, Naim Oueini, Jihad Hawi, Antoine Chrabieh, Laura Dosh, Rosalyn Jurjus, Angelo Leone, Abdo Jurjus

Abstract readReview
PubMed Publisher
In one paragraph

Review in Immunogenetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. From Glycocalyx Shedding to Microvascular Collapse in Sepsis: Endothelial Pathophysiology, Organ Dysfunction, and Mechanistic Biomarkers.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lara DiabDepartment of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Beirut, Lebanon.
Sahar Al KattarDepartment of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Beirut, Lebanon.
Naim OueiniDepartment of Agriculture and Food Engineering, School of Engineering, Holy Spirit University, Kaslik, Jounieh, Lebanon.
Jihad HawiDepartment of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Beirut, Lebanon.
Antoine ChrabiehDepartment of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Beirut, Lebanon.
Laura DoshDepartment of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Beirut, Lebanon.
Rosalyn JurjusDepartment of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Beirut, Lebanon.
Angelo LeoneDepartment of Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, Palermo, Italy.
Abdo JurjusDepartment of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Beirut, Lebanon. aj00@aub.edu.lb.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Syndecan-1 (SDC-1) is a transmembrane protein localized on the basolateral surface of epithelial cells, encompassing a core protein with heparin sulfate and chondroitin sulfate glycosaminoglycan side chains. SDC-1 is involved in a panoply of cellular mechanisms including cell-to-cell adhesion, extracellular matrix interactions, cell cycle modulation, and lipid clearance. Alterations in the expression and function of SDC-1 are implicated in numerous disease entities, making it an attractive diagnostic and therapeutic target. However, despite its broad involvement in several disease processes, the underlying mechanism contributing to its diverse functions, pathogenesis, and therapeutic uses remains underexplored. Therefore, this review examines the role of SDC-1 in health and disease, focusing on liver pathologies, inflammatory diseases, infectious diseases, and cancer, and sheds light on SDC-1-based therapeutic approaches. Moreover, it delves into the mechanisms through which SDC-1 contributes to these diseases, emphasizing cell-type specific mechanisms. By comprehensively summarizing the significance of SDC-1, its association with several diseases, and its underlying mechanisms of action, the findings of this review could inform future research directions toward the development of targeted therapies and early diagnosis for a multitude of disease entities.

Indexed as

NeoplasmsSyndecan-1AnimalsHumansInflammationLiver DiseasesSDC1 protein, humanSyndecan-1CancerInfectious diseaseInflammationLiver diseaseSyndecan-1Therapy

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.